Heparin, Low-Molecular-Weight
"Heparin, Low-Molecular-Weight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
| Descriptor ID |
D006495
|
| MeSH Number(s) |
D09.698.373.400.300
|
| Concept/Terms |
Heparin, Low-Molecular-Weight- Heparin, Low-Molecular-Weight
- Heparin, Low Molecular Weight
- LMWH
- Low Molecular Weight Heparin
- Low-Molecular-Weight Heparin
|
Below are MeSH descriptors whose meaning is more general than "Heparin, Low-Molecular-Weight".
Below are MeSH descriptors whose meaning is more specific than "Heparin, Low-Molecular-Weight".
This graph shows the total number of publications written about "Heparin, Low-Molecular-Weight" by people in this website by year, and whether "Heparin, Low-Molecular-Weight" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 3 | 4 |
| 2012 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin, Low-Molecular-Weight" by people in Profiles.
-
Risk factors for MACE and bleeding in atrial fibrillation patients undergoing surgery: Insights from the bridge trial. J Stroke Cerebrovasc Dis. 2024 Sep; 33(9):107839.
-
Efficacy and Safety of Direct Oral Anticoagulants Compared With Heparin for Preventing Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2023 Jan-Dec; 29:10760296231164355.
-
Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the minimally invasive approach. J Surg Oncol. 2023 Mar; 127(3):413-425.
-
Off-the-shelf, heparinized small diameter vascular graft limits acute thrombogenicity in a porcine model. Acta Biomater. 2022 10 01; 151:134-147.
-
Thromboprophylaxis; what is the future, for high risk surgical patients? Phlebology. 2022 03; 37(2):81-83.
-
Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. Cerebrovasc Dis. 2021; 50(3):245-261.
-
Timing and characteristics of venous thromboembolism after noncancer surgery. J Vasc Surg Venous Lymphat Disord. 2021 07; 9(4):859-867.e2.
-
The use of enoxaparin as bridge to therapeutic INR after LVAD implantation. J Cardiothorac Surg. 2020 Nov 14; 15(1):329.
-
Current Trends in Anticoagulation Bridging for Patients With Chronic Atrial Fibrillation on Warfarin Undergoing Endoscopy. Am J Cardiol. 2018 06 15; 121(12):1548-1551.
-
Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. Indian Heart J. 2016 Jul-Aug; 68(4):464-72.